Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by The University of Texas Health Science Center at San Antonio
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Devalingam Mahalingam, The University of Texas Health Science Center at San Antonio Identifier:
First received: July 22, 2009
Last updated: September 16, 2013
Last verified: September 2013

This study is an open label non randomized study of hydroxychloroquine (HCQ) with histone deacetylase (HDAC) inhibitor Vorinostat in patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and to evaluate the safety and antitumor activity of this drug combination.

Condition Intervention Phase
Malignant Solid Tumour
Drug: Hydroxychloroquine ( HCQ)
Drug: Vorinostat (Suberoylanilide Hydroxamic Acid)
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer

Resource links provided by NLM:

Further study details as provided by The University of Texas Health Science Center at San Antonio:

Primary Outcome Measures:
  • Maximum tolerated dose (MTD) of Hydroxychloroquine (HCQ) in combination with Vorinostat in patients with advanced solid tumors [ Time Frame: 6+ months, MTD is assessed during the 1st cycle ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of HCQ in combination with Vorinostat in this patient population as determined by toxicity profile, incidence and rating according to NCI/CTC v3.0 criteria. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • To evaluate the antitumor activity of HCQ in combination with Vorinostat as determined by response rate and progression free survival (exploratory) [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 48
Study Start Date: November 2009
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Hydroxychloroquine and Vorinostat Drug: Hydroxychloroquine ( HCQ)
The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
Drug: Vorinostat (Suberoylanilide Hydroxamic Acid)
Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.


Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be at least 16 years of age
  • Patients must have a histologically confirmed non-hematological malignancy. Patients must have received and failed standard treatment for their malignancy; patients for whom no standard treatment is available will also be eligible.
  • Patients must have an ECOG PS at 0, 1, or 2
  • Patients must have adequate hematologic, renal and liver function (i.e. absolute Neutrophil count > 1000/mm3, platelets > 75,000/mm3); creatinine

    • 2 times the upper limits of normal (ULN) total bilirubin ≤ 1.5 mg/dl, ALT and AST £ 3 times above the upper limits of the institutional norm ALT, AST can be < 5 times upper limits of normal if patients have hepatic involvement.
  • Patients must be able to provide written informed consent.
  • Patients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Women of childbearing potential must have a negative pregnancy test. The anti-proliferative activity of this experimental drug may be harmful to the developing fetus or nursing infant.
  • Complete supportive and palliative care will continue to be provided to ameliorate signs and symptoms that were pre-existing or may arise while on study and which do not interfere with the objectives of the study.
  • Tumor blocks available from previous surgery/biopsy.

At the tumor specific expansion, only patients with metastatic colorectal and renal cell cancers will be enrolled. Patients with metastatic colorectal and renal cancer must have been treated and progressed or intolerant to standard care therapy.

Patients with colorectal cancer must been treated in the past with Irinotecan and/or Oxaliplatin and/or AvastinIEGFR therapy or intolerant to these agents. No more than 4 lines of therapy permitted in the metastatic setting. Patients with colorectal cancer may enroll irrespective of K-Ras mutational status, although this will be documented.

Patients with renal cell cancer must have been treated with a VEGF targeted therapy and/or mTOR inhibitor. No more than 4 lines of therapy permitted in the metastatic setting.

Prior treatment with Vorinostat and HCQ are not permitted in each tumor type.

Exclusion Criteria:

  • Patients with uncontrolled brain metastases.
  • Due to risk of disease exacerbation patients with porphyria are not eligible.
  • Due to risk of disease exacerbation patients with psoriasis are ineligible unless the disease is well controlled and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbations.
  • Patients with previously documented macular degeneration or diabetic retinopathy.
  • Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for Nitrosoureas or Mitomycin C) prior to entering the study or those who have not recovered from adverse events to ≤ grade 1 due to agents administered more than 4 weeks earlier. For targeted therapies patients will need to clear for 5 half lives.
  • Patients may not be receiving any other investigational agents.
  • Patients should not have taken valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to enrollment.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or HCQ.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Major surgery or significant traumatic injury occurring within 21 days prior to treatment.
  • Clinically significant hypercalcemia (including vomiting, dehydration and neurological symptoms).
  • QTc > 500 ms at baseline (average of 3 determinations at 10 minutes interval).
  • Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease. Patients with NJ, J or G tube will not be allowed to participate.
  • Pregnant women are excluded from this study because SAHA has the potential for teratogenic or abortifacient effects
  • Patients with known hepatitis B or C or HIV infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01023737

Contact: Epp Goodwin 210-450-5798

United States, Texas
Cancer Therapy & Research Center University of Texas Health Science Center San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Epp Goodwin    210-450-5798   
Principal Investigator: Devalingam Mahalingam, MD         
Sponsors and Collaborators
Devalingam Mahalingam
Merck Sharp & Dohme Corp.
Principal Investigator: Devalingam Mahalingam, MD University of Texas Health Science Center San Antonio
  More Information

No publications provided

Responsible Party: Devalingam Mahalingam, Principal Investigator, The University of Texas Health Science Center at San Antonio Identifier: NCT01023737     History of Changes
Other Study ID Numbers: IDD 08-52
Study First Received: July 22, 2009
Last Updated: September 16, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by The University of Texas Health Science Center at San Antonio:
Malignant Solid Tumor
Solid Tumor

Additional relevant MeSH terms:
Anti-Infective Agents
Antineoplastic Agents
Antiparasitic Agents
Antiprotozoal Agents
Antirheumatic Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 20, 2014